Drug name - Orladeyo
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(12 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(17 years from now) | |
| CN106257976A | BIOCRYST | Human Plasma Kallikrein Inhibitor |
Mar, 2035
(12 years from now) | |
| CN106257976B | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772A1 | BIOCRYST | Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772A4 | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772B1 | BIOCRYST | Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772B8 | BIOCRYST | Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(17 years from now) | |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 110MG BASE | CAPSULE;ORAL | Prescription |
| EQ 150MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.